

Thursday 10th February 2005

FOR IMMEDIATE RELEASE

OBJ LODGES FIRST DRUG SPECIFIC DELIVERY PATENT

OBJ Limited (OBJ) is pleased to announce that it has lodged a provisional patent specification covering the specific Dermaportation energy fields used to successfully mobilise lignocaine hydrochloride and prilocaine hydrochloride, two topical anaesthetic drugs.

This is the first of a number of patent applications covering the specific relationship between the proprietary transdermal delivery fields used by OBJ and the molecular structure of a particular drug. This patent application is a further enhancement to OBJ's current patent and IP programme.

In independent University tests, OBJ's drug delivery has been shown to increase rates of drug delivery by up to 600% and to reduce drug delivery times by up to 70%.

The company was able, to achieve these results and lodge its provisional specification in time for submission to the World Congress on Pain, to be held in Sydney in August 2005.

This will provide OBJ with an opportunity to present its new drug delivery technology and its encouraging results at an international forum attended by all major pharmaceutical companies.

Independent University testing will begin shortly on a number of additional drugs and compounds used in the cosmetic, oncology, dermatology and endocrinology markets.

ENDS

OBJ Limited (ACN 056 482 636)

Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007

Phone: +61 9 9443 3011 Fax: +61 9 9443 3866 Email: jedwards@obi.com.au

OBJ
LIMITED

RESEARCH & DEVELOPMENT

OBJ
LIMITED

PERMISSION REQUIRED TO REPRODUCE

Background to the Announcement

OBJ Limited is a drug delivery company, developing electronic "drug patch" technologies that allow drugs, therapeutic agents and cosmetic compounds to be delivered more effectively and more efficiently through-the-skin.

OBJ's technology works by temporarily changing the skin's barrier effect. As this does not involve a change to the target drug or compound, new and effective delivery strategies can be created without the necessity for the drug to undergo costly re-registration. This provides pharmaceutical companies with a market friendly, cost effective and safe route of administration for many existing and newly created drugs and compounds.

The company had previously announced a 600% increase in the rate of delivery of the drug caffeine and a 70% reduction in the through-the-skin delivery times for the anaesthetic drugs lignocaine and prilocaine hydrochloride.

Independence of Results

OBJ contracts its drug and technology testing programs to independent and respected organisations, such as Western Australian Biomedical Research Institute or WABRI and Universities.

WABRI is a government owned and funded drug development and testing facility operated by Curtin University. The high level of independence and international accreditation means that the results by OBJ can be published and presented at major medical and scientific conferences and forums.

Drug testing Program and Continuous disclosure

OBJ has a continuous drug testing program designed to cover a broad range of existing drugs and compounds used commercially by the cosmetic, oncology, dermatology, endocrinology and general practice sectors.

For more information:

OBJ Limited
Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007
Phone: +61 8 9443 3011
Fax: +61 8 9443 3866
Email: jedwards@obj.com.au